Kevin Harrington Looks Forward to CONCORDE Study Results on DNA Damage Inhibitors and Radiotherapy
Kevin Harrington, Professor in Biological Cancer Therapies at Institute of Cancer Research, shared Gerry Hanna’s post on LinkedIn:
“Looking forward to seeing the results of CONCORDE and, in particular, further evidence of the immune effects of DNA damage response inhibitors combined with radiotherapy.”
Quoting Gerry Hanna’s post about a recent paper by Magnus T. Dillon et al. published on Nature:
“Thanks to Fiona Hegi Johnson for flagging Peter MacCallum Cancer Centre Radiation Oncology fellow Magnus Dillon’s paper on the PATRIOT study. This highly innovative study was led by the ICR London’s Kevin Harrington.
This paper reports the clinical results reporting highly encouraging responses with such low doses of hashtag#radiotherapy in combination with DNA damage repair inhibitor Ceralasertib (ATR inhibitor AZD6738).
Of note the authors report that there we no observed response trends with genetic abberation, but there was increased T and NK cell activation in peripheral blood.
Looking forward to seeing how this combination performs in the Cancer Research UK (CRUK) funded CONCORDE study.”
Title: Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial
Authors: Magnus T. Dillon, Emmanuel C. Patin, Kabir Mohammed, Jeane Guevara, Simon A. Smith, Emma Dean, Heba Soliman, Pablo Nenclares, Motoko Ryugenji, Davina Northcote, Neel Shah, Lorna Grove, Christopher J. Lord, Stephen Pettit, Matt Tall, Karen E. Swales, Udai Banerji, Alan A. Melcher, Mark Saunders, Martin D. Forster and Kevin J. Harrington
More posts featuring Kevin Harrington.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023